Anne E. White - 12 Feb 2024 Form 4 Insider Report for ELI LILLY & Co (LLY)

Reporting relationship
EVP & Pres, Lilly Neuroscience
Issuer ticker
LLY
Reported as of
12 Feb 2024
Net transaction value
+$3,953,925
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
14 Feb 2024, 16:44:44 UTC
Prior SEC filing
02 Feb 2024
Next SEC filing
04 Feb 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Jonathan Groff for Anne E. White, pursuant to authorization on file

Key filing fact

Anne E. White filed Form 4 for ELI LILLY & Co (LLY) on 14 Feb 2024.

Key facts

  • This page summarizes Anne E. White's Form 4 filing for ELI LILLY & Co (LLY).
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 14 Feb 2024, 16:44.

Change

  • Previous filing in this sequence was filed on 02 Feb 2024.
  • Current net transaction value: +$3,953,925.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LLY transaction

Common Stock

Award

Transaction value
$3,953,925
Shares
+5,363
Change %
+8.9%
Price
$737.26
Shares after
65,569
Date
12 Feb 2024
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LLY transaction Derivative

Restricted Stock Unit

Award

Transaction value
$0
Shares
+3,269
Change %
Price
$0.000000
Shares after
3,269
Date
12 Feb 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
3,269
Exercise price
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .